Prostate Cancer - Results from #1300

EORTC 2238 "De-Escalate": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors. May 24, 2024

Clarity Update: Complete Response in First Patient Ever Treated with 2 Doses of Cu-67 SAR-bisPSMA at 8GBq May 23, 2024

Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer. May 23, 2024

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. May 23, 2024

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. May 23, 2024

Between Pathological Prostate Cancer Lymph Nodes and Sentinel Nodes: Which Information Is the Leader? May 23, 2024

Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. May 23, 2024

Comparison of Multiparametric MRI and the Combination of PSMA Plus MRI for the Intraprostatic Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. May 23, 2024

Radiomic nomogram based on bi-parametric magnetic resonance imaging to predict the International Society of Urological Pathology grading ≥ 3 prostate cancer: a multicenter study. May 22, 2024

Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm. May 22, 2024

Da Vinci vs. Hugo RAS for robot-assisted radical prostatectomy: a prospective comparative single-center study. May 22, 2024

Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor. May 22, 2024

Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study. May 22, 2024

Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors. May 22, 2024

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. May 21, 2024

Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. May 21, 2024

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. May 21, 2024

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. May 21, 2024

SpaceOAR Complication Affecting the Treatment of Prostate Cancer. May 21, 2024

Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. May 21, 2024

Page 66 of 1458